Protalix BioTherapeutics, Inc. (NYSE: PLX) announced that based on guidance and feedback from the U.S. Food and Drug Administration (FDA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE